DLL3 and neoplasm: Targeting the DLL3/Notch4 axis instead allowed to affect tumor-derived endothelial cells and neoplastic angiogenesis upregulated under doxorubicin therapy by reducing Notch4-driven transcription of VEGFR3 [471].